The definitive guide to gene editing.
Menu
Home Learn News Ask the Atlas
Explore Technologies Diseases Treatments Clinical Trials Companies Scientists Genes Research Institutions
Beyond medicine Agriculture Ethics Investing World map
Learn & Tools Start here Glossary A–Z Compare technologies Timeline Lists & Rankings AI Agents ★ Saved API
About About us Methodology Data Sources Editorial Policy Contact Disclaimers

🧭 Guided View
New to genetics? We explain every term as you browse, in plain English. Same pages, with the help built in.

⚡ Expert View
You already know the biology. Just the content — clean and compact, no extra explanations. This is the default view.

Interface language
Light mode

Technology · RNA targeting

CRISPR-Cas13

Targets RNA rather than DNA, so it can silence a gene's message without touching the genome itself.

Phase I RNAreversiblediagnostics
Clinical research Being tested in people in registered clinical trials. Being in trials is not evidence that a treatment works or is safe.

Simple explanation

Every other CRISPR system here goes after DNA — the permanent copy of the instructions. Cas13 goes after RNA, the working copies the cell makes from those instructions. Destroy the working copies and the protein stops being made, but the original is untouched. That means the effect wears off, which is sometimes exactly what you want: a treatment you can stop is safer than one you cannot.

Go deeper

Cas13 (type VI) effectors are RNA-guided RNA endonucleases with two HEPN domains. Guided by a crRNA to a complementary transcript, Cas13 cleaves it, knocking down gene expression without altering genomic DNA. Like Cas12a it shows collateral activity — against RNA — which is the basis of the SHERLOCK diagnostic platform. Catalytically dead Cas13 fusions enable programmable RNA base editing (REPAIR, RESCUE).

Why targeting RNA is different

A DNA edit is permanent by design: if it is wrong, it stays wrong. An RNA-targeting therapy has to be re-dosed, because the cell keeps making fresh transcripts — an inconvenience that doubles as a safety feature. It also means there is no risk of a heritable change and no double-strand break to repair.

The trade-off is that RNA targeting cannot fix anything. It reduces the amount of a protein being made. For conditions caused by a toxic protein that is useful; for conditions caused by a missing protein it is not.

Diagnostics

Cas13's collateral RNA cleavage powers SHERLOCK, which pairs isothermal amplification with a fluorescent reporter to detect specific nucleic-acid sequences at very low concentration — an approach deployed for viral detection including during the COVID-19 pandemic.

Diagnostics
A Cas13 effector engaging a single-stranded RNA transcript rather than DNA. Illustration generated for The CRISPR Atlas — a visual aid, not a photograph or a literal depiction of molecular structure.

Clinical status

Clinical work is early. Programmes have explored RNA knockdown in the eye and in genetic disease, and Cas13's reversibility makes it attractive where a permanent change would be hard to justify. Off-target and collateral activity in human cells has been a recurring concern in the literature and is an active area of engineering.

Sources

Connected in the Atlas

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.

Educational information only This page is a reference, not medical advice. Research and regulatory status change; check the last-updated date above and confirm anything important against the primary sources listed.